Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer's early-stage compounds, including data from Pfizer's investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.
“The data being presented at this meeting highlight preclinical research that has helped to shape our clinical development strategies.”
"The data we will present at AACR are representative of our continued commitment to emerging science and to advancing research and development in the area of antibody-drug conjugates," said Bob Abraham, PhD, senior vice president and chief scientific officer, Oncology Research Unit. "With expert scientists and complete in-house capabilities in this unique targeted therapy platform, our goal is to discover and develop the next generation of ADCs that may provide improved treatment options for patients with cancer."
ADC-based cancer therapies use a targeted antibody to deliver a cytotoxin directly to specific tumor cells, with the goal of enhancing the anti-tumor activity of an antibody while reducing the toxicity of the cytotoxin on healthy cells. At the meeting, Pfizer will present data on several of the ADCs in its portfolio, including an analysis from an ongoing Phase 2 study (Study 2001) of inotuzumab ozogamicin in patients with refractory or relapsed indolent B-cell Non-Hodgkin's lymphomas (Abstract #3776, April 3).
The following data evaluating ADCs will also be featured:
- The use of pharmacokinetic-pharmacodynamic modeling to characterize platelet response following inotuzumab ozogamicin treatment in patients with follicular or diffuse large B-cell NHL (Abstract #3767, April 3)
- Long-term tumor regression induced by a novel ADC that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells (Abstract #2530, April 2)
- Novel site-specific ADCs based on novel amino acid incorporation technology have improved pharmaceutical properties over conventional ADCs (Abstract #5691, April 4)
Additional Research Reflects Emerging Science
Pfizer will present further data relating to its pipeline and preclinical studies in emerging areas of cancer research.
"Over the past 12 months, Pfizer has launched two new oncology drugs in the U.S., filed a third for review, and focused our early portfolio on the development of innovative compounds that hold the greatest potential in areas of unmet need," said Mace Rothenberg, MD, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "The data being presented at this meeting highlight preclinical research that has helped to shape our clinical development strategies."
Data being presented from Pfizer's early development portfolio include: